Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction.

[1]  I. Ockene,et al.  Varenicline for smoking cessation in patients with coronary heart disease. , 2010, Circulation.

[2]  U. Goldbourt,et al.  Smoking status and long-term survival after first acute myocardial infarction a population-based cohort study. , 2009, Journal of the American College of Cardiology.

[3]  B. Make,et al.  Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. , 2008, American journal of health behavior.

[4]  Rachel E. Anderson,et al.  High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. , 2008, American heart journal.

[5]  J. Avorn,et al.  Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. , 2008, Journal of the American College of Cardiology.

[6]  J. Avorn,et al.  Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons > or =65 years of age. , 2007, The American journal of cardiology.

[7]  J. Tu,et al.  Inpatient smoking-cessation counseling and all-cause mortality in patients with acute myocardial infarction. , 2007, American heart journal.

[8]  M. Eisenberg,et al.  Smoking cessation in patients with coronary artery disease. , 2005, American heart journal.

[9]  Steven Hawken,et al.  Preventive cardiologyAbstractsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study , 2004 .

[10]  A J Dobson,et al.  Current smoking and the risk of non-fatal myocardial infarction in the WHO MONICA Project populations , 2004, Tobacco Control.

[11]  R. Edwards.  The problem of tobacco smoking , 2004, BMJ : British Medical Journal.

[12]  S. Tonstad,et al.  Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. , 2003, European heart journal.

[13]  J. Critchley,et al.  Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. , 2003, JAMA.

[14]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[15]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[16]  Nicholas Smith,et al.  Smoking Status and Risk for Recurrent Coronary Events after Myocardial Infarction , 2002, Annals of Internal Medicine.

[17]  A. Gavazzi,et al.  [Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[18]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[19]  P. Toutouzas,et al.  In-hospital mortality of habitual cigarette smokers after acute myocardial infarction; the "smoker's paradox" in a countrywide study. , 2001, European heart journal.

[20]  V. Boyko,et al.  Smoking and prognosis after acute myocardial infarction in the thrombolytic era (Israeli Thrombolytic National Survey). , 1996, Journal of the American College of Cardiology.

[21]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[22]  M. Pfeffer,et al.  Rationale, design and baseline characteristics of the survival and ventricular enlargement trial , 1991 .

[23]  S. Shapiro,et al.  Decline in the risk of myocardial infarction among women who stop smoking. , 1990, The New England journal of medicine.

[24]  R. Lassila,et al.  Enhanced activation of the renin‐angiotensin‐aldosterone system in chronic cigarette smokers: A study of monozygotic twin pairs discordant for smoking , 1988, Clinical pharmacology and therapeutics.

[25]  S. Shapiro,et al.  The risk of myocardial infarction after quitting smoking in men under 55 years of age. , 1985, The New England journal of medicine.

[26]  E. Gilpin,et al.  Smoking status at the time of acute myocardial infarction and subsequent prognosis. , 1985, American heart journal.

[27]  G. Bigelow,et al.  Smoking following myocardial infarction: a critical review of the literature. , 1984, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[28]  W. Abelmann,et al.  Acute Hemodynamic Effects of Cigarette Smoking in Man Assessed by Systolic Time Intervals and Echocardiography , 1979, Circulation.